- Home
- BFLY vs PROK Comparison
BFLY vs PROK Comparison
Compare BFLY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFLY | PROK |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Medical Electronics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 331.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFLY | PROK |
|---|---|---|
| Price | $3.89 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.88 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 5.8M | 559.7K |
| Earning Date | 05-01-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $22.37 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $1.32 | $0.46 |
| 52 Week High | $5.03 | $7.13 |
Technical Indicators
Market Signals| Indicator | BFLY | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 36.74 |
| Support Level | $3.59 | $1.71 |
| Resistance Level | $4.03 | $2.58 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 46.25 | 7.75 |
Price Performance
Historical ComparisonAbout BFLY Butterfly Network Inc.
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.